Orchestra BioMed Loss Widens as Pivotal Trials Advance
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) widened its second-quarter loss by 23% as spending increased on two pivotal cardiovascular trials, while $35 million of strategic capital …
Orchestra BioMed Loss Widens as Pivotal Trials Advance Read More